BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its lone marketed therapy.

BridgeBio Pharma BBIO is building its investment case around rare diseases where diagnosis, targeted treatment and commercial access are changing quickly. Attruby's launch in tran ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...

BBIO’s Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. This candidate positions BBIO against Pfizer’s Tafamidis and Alnylam’s Amvuttra. Its US uptake keeps ...

- Attruby (acoramidis) is rapidly becoming the first-choice therapy for newly diagnosed ATTR-CM patients with 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, 2025, ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectively ...

Shares of BridgeBio Pharma BBIO climbed to a 52-week high of $93.42 on Thursday after rival AstraZeneca's AZN late-stage clinical setback boosted investor confidence in the company's sole marketed ...

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue ...